DrugPatentWatch Database Preview
Celgene Intl Company Profile
» See Plans and Pricing
What is the competitive landscape for CELGENE INTL, and when can generic versions of CELGENE INTL drugs launch?
CELGENE INTL has one approved drug.
There are three US patents protecting CELGENE INTL drugs.
There are twenty-seven patent family members on CELGENE INTL drugs in twenty-two countries and six supplementary protection certificates in six countries.
Summary for Celgene Intl
| International Patents: | 27 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Celgene Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | Start Trial | Start Trial | |||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | 9,382,217 | Start Trial | Start Trial | ||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | 8,481,573 | Start Trial | Y | Y | Start Trial | ||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | 8,481,573 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celgene Intl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2291080 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009151529 | Start Trial |
| Japan | 2016041736 | Start Trial |
| Croatia | P20150982 | Start Trial |
| Eurasian Patent Organization | 201001785 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Intl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2291080 | PA2020529 | Lithuania | Start Trial | PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520 |
| 2291080 | LUC00177 | Luxembourg | Start Trial | PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525 |
| 2291080 | CA 2020 00047 | Denmark | Start Trial | PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200520 |
| 2291080 | 301065 | Netherlands | Start Trial | PRODUCT NAME: OZANIMOD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER OZANIMODHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/20/1442 20200525 |
| 2291080 | 122020000055 | Germany | Start Trial | PRODUCT NAME: OZANIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE OZANIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/20/1442 20200520 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
